ajanta pharma limited

AJANTA HOUSE
Charkop, Kandivli (W),
MUMBAI - 400 067. INDIA
Tel. : (+91)22-6606 1000
Fax : (+91)22-6606 1200 / 300
E-mail : info@ajantapharma.com
Website : www.ajantapharma.com

22nd October, 2010

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001.

Dear Sir,

Re: Clause 41
Scrip Code: BSE - AJANTAPH 532331
NSE - AJANTPHARM EQ

Pursuant to Clause 41 of the Listing Agreement, we are enclosing herewith Unaudited Financial Results for the second quarter and half year ended 30th September, 2010 duly signed by the Managing Director. These results were approved by the Board of Directors at their Meeting held on Friday, 22nd October, 2010.

Kindly acknowledge receipt.

Thanking You,

Yours faithfully,
For **AJANTA PHARMA LIMITED**

NIKHIL BHATT
G.M. - Legal &
Company Secretary

Encl.: a/a

c.c. : National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051.

ajanta pharma limited

Regd.Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67

Stand Alone Financial Results for the quarter ended 30th September, 2010

Rupees Lakhs

Particulars	3 months ended		6 months ended		Year Ended
	30/09/2010	30/09/2009	30/09/2010	30/09/2009	31/03/2010
	Unaudited		Unaudited		Audited
1. Net Sales/Income from Operations	11,250.62	9,459.19	21,079.29	17,912.36	38,166.85
2. Expenditure					
a. (Increase)/decrease in stock in trade and work in progress	(373.13)	(301.47)	(1,308.01)	(360.63)	1,630.53
b. Consumption of raw & packing materials	3,828.37	3,046.98	7,460.88	5,325.56	11,227.29
c. Purchase of traded goods	657.59	445.22	1,120.72	1,197.22	2,058.34
d. Employees cost	1,382.70	1,161.85	2,720.90	2,156.49	4,452.08
e. Depreciation	589.94	449.01	1,102.08	880.09	1,975.56
f. Research & Development Expenses	483.76	553.48	1,016.13	1,078.61	2,026.45
g. Other expenditure	3,179.56	2,800.27	6,191.19	5,224.76	9,650.55
h. Total	9,748.79	8,155.34	18,303.89	15,502.10	33,020.80
3. Profit from Operations before Other Income, Interest & Exceptional Items	1,501.83	1,303.85	2,775.40	2,410.26	5,146.05
4. Other Income	36.00	30.17	56.52	34.75	127.35
5. Profit before Interest & Exceptional Items	1,537.83	1,334.02	2,831.92	2,445.01	5,273.40
6. Interest	435.22	596.90	870.33	1,094.87	1,907.29
7. Profit after Interest but before Exceptional Items	1,102.61	737.12	1,961.59	1,350.14	3,366.11
8. Exceptional Items	-	-	-	-	-
9. Profit from Ordinary Activities before tax	1,102.61	737.12	1,961.59	1,350.14	3,366.11
10. Tax Expense	97.45	94.13	258.55	269.72	512.34
11. Net Profit from Ordinary Activities after tax	1,005.16	642.99	1,703.04	1,080.42	2,853.77
12. Extraordinary Items (net of tax expense)	-	-	-	-	-
13. Net Profit for the period	1,005.16	642.99	1,703.04	1,080.42	2,853.77
14. Paid-up Equity Share Capital (Face value of Rs. 10/- each)	1,179.61	1,179.61	1,179.61	1,179.61	1,179.61
15. Reserve excluding Revaluation Reserve	NA	NA	NA	NA	16,411.07
16. Earnings Per Share (EPS)					
Basic and diluted (not annualised) - Rs.	8.58	5.49	14.55	9.23	24.37
17. Public Shareholding					
- Number of shares	3884879	3884879	3884879	3884879	3884879
- Percentage of shareholding	33.18%	33.18%	33.18%	33.18%	33.18%
18. Promoters and promoter group shareholding					
a) Pledged/Encumbered					
- Number of shares	200000	3035000	200000	3035000	200000
- Percentage of total promoter's holding	2.56%	38.79%	2.56%	38.79%	2.56%
- Percentage of total share capital of company	1.71%	25.92%	1.71%	25.92%	1.71%
b) Non-encumbered					
- Number of shares	7623621	4788621	7623621	4788621	7623621
- Percentage of total promoter's holding	97.44%	61.21%	97.44%	61.21%	97.44%
- Percentage of total share capital of company	65.11%	40.90%	65.11%	40.90%	65.11%

Balance Sheet

Rupees Lakhs

Particulars	As At 30/09/2010	As At 31/03/2010
	Unaudited	Audited
SHAREHOLDERS FUND		
(a) Capital	1,179.61	1,179.61
(b) Reserves and Surplus	18,114.12	16,411.07
LOAN FUNDS	17,881.48	20,329.09
DEFERRED TAX LIABILITY	838.09	580.09
Total	38,013.30	38,499.86
FIXED ASSETS	21,386.49	20,784.29
INVESTMENTS	1,705.13	1,705.14
CURRENT ASSETS, LOANS AND ADVANCES		
(a) Inventories	10,560.28	10,516.13
(b) Sundry Debtors	6,589.87	8,550.41
(c) Cash and Bank balances	316.70	523.39
(d) Loans and Advances	4,319.15	3,848.44
Less: Current Liabilities and Provisions		
(a) Liabilities	6,580.05	6,666.31
(b) Provisions	284.27	761.63
Total	38,013.30	38,499.86

Notes :

1. Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 22nd October, 2010.
2. Statutory Auditors have carried out Limited Review of the above results.
3. The company has only one segment of activity namely, Pharmaceuticals.
4. Investor's Complaints status - Opening - 0, Received - 7, Resolved - 7, Closing - 0.
5. Previous period's figures have been regrouped wherever necessary.

By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director

Mumbai, 22nd October, 2010